{"id":"NCT02667288","sponsor":"Aclaris Therapeutics, Inc.","briefTitle":"An Open-Label Safety Study of A-101 Solution","officialTitle":"An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01","primaryCompletion":"2016-10","completion":"2016-10","firstPosted":"2016-01-28","resultsPosted":"2017-11-17","lastUpdate":"2018-02-07"},"enrollment":147,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Seborrheic Keratosis"],"interventions":[{"type":"DRUG","name":"A-101 Solution","otherNames":[]}],"arms":[{"label":"A-101 Solution","type":"EXPERIMENTAL"}],"summary":"This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.","primaryOutcome":{"measure":"Proportion of Subjects With Lesion Clearance","timeFrame":"Study day 148","effectByArm":[{"arm":"A-101 Solution","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":147},"commonTop":["Cough","Seasonal Allergy","Sinusitis","Actinic Keratosis","Anemia"]}}